St Jude CE-marks cardiac ICD (implantable cardioverter defibrillator) and pacemaker devices:
This article was originally published in Clinica
St Jude Medical has gained the European go-ahead to sell both its rate-adaptive Atlas DR/VR implantable cardioverter defibrillator (ICD) and its Identity pacemaker devices for the treatment of patients with cardiac rhythm abnormalities. The Atlas ICD device, which is implanted under the skin, can deliver several magnitudes of electrical shock to patients with ventricular tachycardia and fibrillation. Separately, the Identity pacemaker device has both a therapeutic and diagnostic capability for pacemaker patients suffering from atrial fibrillation, said the St Paul, Minnesota firm.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.